Galectin-3 in acute coronary syndrome

Agnello, Luisa; Bivona, Giulia; Sasso, Bruna Lo; Scazzone, Concetta; Bazan, Viviana; Bellia, Chiara; Ciaccio, Marcello

doi:10.1016/j.clinbiochem.2017.04.018

Cited by 71 publications

(60 citation statements)

References 62 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amongst other biomarkers (NPs, GDF-15, high-sensitivity troponin T, sST2, aldosterone, phosphate, parathyroid hormone, plasma renin concentration, and creatinine) galectin-3 had the lowest indices of individual biological variability, whereas NPs and GDF-15 has the highest ones (Meijers et al, 2016). Additionally, in contrast to NPs serum galectin-3 levels did not appear to be significantly related to circulating level of cardiac troponins, left ventricular (LV) ejection fraction and LV mass index (Agnello et al, 2017). Therefore, there was a positive correlation galectin-3 levels with NT-proBNP in HF individuals.…”

Section: Limitations In Use Of Conventional Biomarkers In Hfmentioning

confidence: 86%

Up-to-date clinical approaches of biomarkers’ use in heart failure

Berezin¹

2017

Biomed. Res. Ther.

View full text Add to dashboard Cite

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients' population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.

show abstract

Section: Limitations In Use Of Conventional Biomarkers In Hfmentioning

confidence: 86%

Up-to-date clinical approaches of biomarkers’ use in heart failure

Berezin¹

2017

Biomed. Res. Ther.

View full text Add to dashboard Cite

show abstract

“…It contributes to the reparative processes in the infarcted area, in the early phase, which is essential for the maintenance of LVEF. In the later phase, galectin-3 may support the transition from acute to chronic inflammation and trigger cardiac fibrosis, leading to adverse ventricular remodeling and, finally, heart failure and a decrease in LVEF [27]. With the aim of highlighting the important contribution of galectin-3 to cardiac fibrosis and remodeling, a few recent studies assessing the pharmacologic inhibition of galectin-3 have suggested that this may be a method for the prevention of heart failure [28].…”

Section: Discussionmentioning

confidence: 99%

Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation

et al. 2019

View full text Add to dashboard Cite

Objective: Atrial fibrillation (AF) is common in acute myocardial infarction (AMI), and galectin-3 is possibly involved in its occurrence. Galectin-3 has been shown to play a central role in fibrosis and tissue remodeling and has a role in inflammatory and proliferative responses. The aim of our study was to measure galectin-3 levels in patients with myocardial infarction and to compare its levels in patients with or without AF, in order to investigate the potential predictive role of galectin-3 in this setting. Subjects and Methods: The study included 51 consecutive AMI patients with AF; 27 AMI patients (52.9%) had permanent/persistent AF, and 24 patients (47.1%) had paroxysmal AF. Thirty-eight consecutive AMI patients without AF were used as a control group. Blood samples were obtained from venous blood on the third day after reperfusion. Results: Patients with AF had higher levels of C-reactive protein (p < 0.01) and galectin-3 (p < 0.05) than those without AF. Patients with high galectin-3 had 4.4 times greater odds of having AF. Galectin-3 levels were lower in patients without AF (p < 0.01) than in those with permanent/persistent AF. Conclusion: AMI patients with AF had higher levels of galectin-3 than those without this arrhythmia. This biomarker of inflammation and fibrosis could be a potential target for treating AMI patients at high risk.

show abstract

“…Melting points (MPs) of all prepared compounds were measured on an electrothermal XT5G apparatus (Beijing Keyi Electro-optic Instrument, Beijing, China) and without correction. 1 H nuclear magnetic resonance (NMR) spectra of all prepared compounds were recorded at 500 MHz ( 1 H NMR) and 125 MHz ( 13 C NMR) on a Bruker AVANCE II 500. Optical rotations of all prepared compounds were measured with a Jasco P-1020 Polarimeter.…”

Section: Materials and Methods Generalmentioning

confidence: 99%

“…Arterial thrombosis has been associated with a series of pathologic conditions, such as acute coronary syndromes, [1][2][3] ischemic stroke, 4,5 transient ischemic attack, 5,6 tumor thrombosis, 7,8 recurrence of thromboembolic events, 9,10 metabolic syndrome, [11][12][13][14][15] chronic pain and swelling symptoms. 16 Platelet activation plays an important role in the formation of arterial thrombosis.…”

Section: Introductionmentioning

confidence: 99%

“…Preparation of 3s-N-Boc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (1) At 0°C a solution of 10 g (56.5 mmol) of IQCA and 2.5 g (62.2 mmol) of NaOH in 63 mL of water and a solution of 14.8 g (67.8 mmol) of (Boc) 2 O in 40 mL of tetrahydrofuran were mixed. This mixture was stirred at room temperature for 24 h, TLC (CHCl 3 /CH 3 OH, 10/1) indicated the complete disappearance of IQCA, the solvent was removed under reduced pressure, and the residue was dissolved in 60 mL of ethyl acetate.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA

Zhu

Yang

et al. 2018

IJN

View full text Add to dashboard Cite

Background Arterial thrombosis has been associated with a series of pathological conditions, and the discovery of arterial thrombosis inhibitor is of clinical importance. Methods By analyzing the pharmacophores of anti-platelet agents, thrombus targeting peptide and anti-thrombotic nano-systems 3S-1,2,3,4-tetrahydroisoquino-line-3-carbonyl-Thr-Ala-Arg-Gly-Asp(Val)-Val (IQCA-TAVV) was designed and prepared as a nano-scaled arterial thrombosis inhibitor. Results In vitro the nanoparticles of IQCA-TAVV were able to adhere onto the surface of activated platelets, attenuate activated platelets to extend pseudopodia and inhibit activated platelets to form aggregators. In vivo IQCA-TAVV targeted arterial thrombus, dose dependently inhibited arterial thrombosis with a 1 nmol/kg of minimal effective dose, and the activity waŝ1670 folds of that of aspirin. Conclusion IQCA-TAVV represented the design, preparation and application of nanomedicine capable of adhering on the surface of activated platelets, attenuating platelet activation, targeting arterial thrombus and inhibiting arterial thrombosis.

show abstract

Galectin-3 in acute coronary syndrome

Cited by 71 publications

References 62 publications

Up-to-date clinical approaches of biomarkers’ use in heart failure

Up-to-date clinical approaches of biomarkers’ use in heart failure

Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation

Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA

Contact Info

Product

Resources

About